Clinical trial readout dates for Kymera Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is June 2027.
| Phase 2 KT-621 Atopic Dermatitis · NCT07217015 | June 2027 Ongoing |
| Phase 2 KT-621 Eosinophilic Asthma · NCT07323654 | December 2027 Recruiting |
| Phase 2 KT-621 Asthma (Diagnosis) · NCT07677059 | December 2028 Recruiting |
Kymera Therapeutics Inc. reported $1.65B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $132M; at that rate the cash would last about 12 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-29 |